Corcept Therapeutics (CORT) Tops Q2 EPS by 10c; Reaffirms
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $91.61 +1.55%
EPS Growth %: -96.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: -96.6%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.32, $0.10 better than the analyst estimate of $0.22. Revenue for the quarter came in at $88.6 million versus the consensus estimate of $90.14 million.
GUIDANCE:
Corcept Therapeutics reaffirms FY2020 revenue of $355-375 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
- Morgan Stanley turns cautious on freight stocks despite stronger cycle outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
